Core Viewpoint - The strategic investment by Zhong Shanshan in Jinbo Biological is significant, marking a major cash increase and collaboration in the humanized collagen protein sector, where Jinbo is a leader [2][4][8] Group 1: Investment Details - Jinbo Biological has introduced strategic investors, with Zhong Shanshan's companies participating through a share transfer and subscription agreement, raising up to 2 billion yuan [1][5] - After the transaction, Zhong Shanshan will indirectly control 10.58% of Jinbo Biological, becoming its second-largest shareholder [2][6] - The cash increase of 2 billion yuan will be the largest in the history of the Beijing Stock Exchange [4][5] Group 2: Company Performance - Jinbo Biological has shown continuous growth in operating performance, with revenue and net profit increasing for four consecutive years from 2021 to 2024 [3][9] - The company's revenue is projected to grow from 233 million yuan in 2021 to 1.443 billion yuan in 2024, and net profit from 57 million yuan to 732 million yuan, representing increases of 519% and 1184% respectively [9] - Since its listing in July 2023, Jinbo Biological's stock price has surged over 28 times, with a market capitalization exceeding 40 billion yuan [3][9] Group 3: Strategic Collaboration and Future Plans - Jinbo Biological plans to leverage the strengths of its partnership with Yangshengtang to enhance market capabilities, accelerate industrialization, and improve commercialization [7][8] - The 2 billion yuan raised will be allocated for working capital and the development of a FAST database and product development platform for humanized collagen [8] - Jinbo Biological aims to fill gaps in wound care, orthopedic implants, hair health, and ophthalmic drugs, enhancing its market competitiveness and brand influence [8][9]
锦波生物引战投钟睒睒34亿入股 营收净利四连增股价累涨超28倍